NEW YORK (GenomeWeb News) — Enigma Diagnostics yesterday said it has licensed a “broad range” of technologies from the UK’s Defense Science and Technology Laboratory that will give the company “much greater control” over IP “at the heart” of its real-time PCR systems.
The worldwide exclusive license covers 25 DSTL patents and patent applications. In particular, the license covers the Pyrostart, ResonSense, and Temperature Control, technologies, which Enigma called “important elements” of its RT-PCR systems.
These systems are being developed to rapidly detect and identify pathogens, including bacteria and viruses, in clinical, environmental, and biological samples, Enigma said.
The deal follows an initial license agreement that Enigma signed in 2004 with the group, which is a center of scientific excellence for the UK Ministry of Defense.
The new agreement, which will remain in place until 2026, enables Enigma to sub-license any of the technologies for PCR and non-PCR applications to potential partners and collaborators.
Enigma, which will obtain an undisclosed number of trademarks linked to the IP, will be able to patent improvements that it makes to any of the technologies.